JP2024160287A5 - - Google Patents

Download PDF

Info

Publication number
JP2024160287A5
JP2024160287A5 JP2024129687A JP2024129687A JP2024160287A5 JP 2024160287 A5 JP2024160287 A5 JP 2024160287A5 JP 2024129687 A JP2024129687 A JP 2024129687A JP 2024129687 A JP2024129687 A JP 2024129687A JP 2024160287 A5 JP2024160287 A5 JP 2024160287A5
Authority
JP
Japan
Prior art keywords
formulation
aflibercept
concentration
polysorbate
surfactant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024129687A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024160287A (ja
JP7879902B2 (ja
Filing date
Publication date
Priority claimed from JP2020527828A external-priority patent/JP7536640B2/ja
Application filed filed Critical
Publication of JP2024160287A publication Critical patent/JP2024160287A/ja
Publication of JP2024160287A5 publication Critical patent/JP2024160287A5/ja
Application granted granted Critical
Publication of JP7879902B2 publication Critical patent/JP7879902B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024129687A 2017-11-17 2024-08-06 VEGFR-Fc融合タンパク質製剤 Active JP7879902B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762587733P 2017-11-17 2017-11-17
US62/587,733 2017-11-17
US201862618904P 2018-01-18 2018-01-18
US62/618,904 2018-01-18
JP2020527828A JP7536640B2 (ja) 2017-11-17 2018-11-16 VEGFR-Fc融合タンパク質製剤
PCT/US2018/061644 WO2019099921A2 (en) 2017-11-17 2018-11-16 Vegfr-fc fusion protein formulations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020527828A Division JP7536640B2 (ja) 2017-11-17 2018-11-16 VEGFR-Fc融合タンパク質製剤

Publications (3)

Publication Number Publication Date
JP2024160287A JP2024160287A (ja) 2024-11-13
JP2024160287A5 true JP2024160287A5 (cg-RX-API-DMAC7.html) 2025-04-09
JP7879902B2 JP7879902B2 (ja) 2026-06-24

Family

ID=65041879

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020527828A Active JP7536640B2 (ja) 2017-11-17 2018-11-16 VEGFR-Fc融合タンパク質製剤
JP2024129687A Active JP7879902B2 (ja) 2017-11-17 2024-08-06 VEGFR-Fc融合タンパク質製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020527828A Active JP7536640B2 (ja) 2017-11-17 2018-11-16 VEGFR-Fc融合タンパク質製剤

Country Status (8)

Country Link
US (2) US12156900B2 (cg-RX-API-DMAC7.html)
EP (1) EP3709971A2 (cg-RX-API-DMAC7.html)
JP (2) JP7536640B2 (cg-RX-API-DMAC7.html)
AU (3) AU2018368466B2 (cg-RX-API-DMAC7.html)
CA (1) CA3082899A1 (cg-RX-API-DMAC7.html)
MA (1) MA50908A (cg-RX-API-DMAC7.html)
MX (2) MX2020005170A (cg-RX-API-DMAC7.html)
WO (1) WO2019099921A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019099921A2 (en) 2017-11-17 2019-05-23 Amgen Inc. Vegfr-fc fusion protein formulations
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
WO2019173767A1 (en) * 2018-03-08 2019-09-12 Coherus Biosciences Inc. Stable aqueous formulations of aflibercept
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
WO2020055123A1 (ko) * 2018-09-10 2020-03-19 삼성바이오에피스 주식회사 단백질을 포함하는 액상 조성물
WO2021050687A1 (en) * 2019-09-10 2021-03-18 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
CN114867487A (zh) 2019-11-25 2022-08-05 加利福尼亚大学董事会 用于眼内新生血管的长效vegf抑制剂
EP4190310A4 (en) * 2020-07-31 2024-01-17 Celltrion, Inc. Stable pharmaceutical preparation
IL305010A (en) * 2021-02-17 2023-10-01 Arecor Ltd An aqueous preparation of a transgenic protein structure that includes an FC domain
US11723955B1 (en) * 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition
US12240888B1 (en) * 2024-04-29 2025-03-04 QILU Pharmaceutical, Co., Ltd. Composition comprising aflibercept and a variant thereof, and related methods and uses
WO2025227916A1 (zh) 2024-04-29 2025-11-06 齐鲁制药有限公司 包含阿柏西普和其变体的组合物以及相关方法和应用
JP2026054929A (ja) 2024-09-17 2026-03-30 キオクシア株式会社 メモリシステムおよび制御方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2476934C (en) 2002-02-27 2009-06-16 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
PT1610820E (pt) 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
EP1877438A2 (en) 2005-02-02 2008-01-16 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
CA3142945A1 (en) 2005-03-25 2006-10-05 Regeneron Pharmaceuticals, Inc. Histidine-buffered formulations of vegf antagonist
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CN103816115B (zh) 2010-08-31 2017-06-27 成都康弘生物科技有限公司 一种含有抑制血管增生的融合蛋白的药物组合物及用途
AU2012340107B2 (en) 2011-11-18 2017-06-15 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles
WO2013096221A1 (en) 2011-12-21 2013-06-27 Amgen Inc. Variant fc-polypeptides with enhanced binding to the neonatal fc receptor
CN107115294B (zh) 2012-01-19 2019-10-18 北京康弘生物医药有限公司 一种含有vegf拮抗剂的滴眼液
US20130323242A1 (en) * 2012-06-01 2013-12-05 Ophthotech Corp. Compositions comprising an anti-pdgf aptamer and a vegf antagonist
JP2015519373A (ja) 2012-06-01 2015-07-09 オプソテック コーポレイションOphthotech Corporation 抗pdgfアプタマーおよびvegf拮抗薬を含む組成物
UA115789C2 (uk) * 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
WO2014078627A1 (en) 2012-11-19 2014-05-22 Merck Sharp & Dohme Corp. Liquid formulations for tnfr:fc fusion proteins
MX377714B (es) 2013-10-18 2025-03-11 Regeneron Pharma Composiciones que comprenden una combinación de un antagonista de vegf y un anticuerpo anti-ctla-a.
CN105435222B (zh) 2014-09-25 2018-05-29 信达生物制药(苏州)有限公司 重组融合蛋白制剂
KR101808234B1 (ko) 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
MX390837B (es) 2015-10-16 2025-03-21 Regeneron Pharma Composiciones de proteinas estables.
MY200764A (en) * 2015-12-16 2024-01-14 Regeneron Pharma Compositions and methods of manufacturing protein microparticles
EP3407868A1 (en) 2016-01-26 2018-12-05 Formycon AG Liquid formulation of a vegf antagonist
WO2017168296A1 (en) 2016-03-29 2017-10-05 Navya Biologicals Pvt. Ltd A process for purification of fc-fusion proteins
KR101685532B1 (ko) 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
WO2018063963A1 (en) 2016-09-28 2018-04-05 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
ES3064802T3 (en) 2016-10-21 2026-04-29 Amgen Inc Pharmaceutical formulations and methods of making the same
CN109937034B (zh) 2016-11-21 2022-09-16 济世-伊沃泰克生物制品有限公司 阿柏西普制剂及其用途
BR112019011900A2 (pt) 2016-12-23 2019-11-26 Serum Institute Of India Private Limited métodos melhorados para aumentar a produtividade de anticorpos na cultura de células de mamíferos e minimizar a agregação durante os processos downs-tream, processos de formulação, e formulações de anticorpos estáveis obtidas dos mesmos
KR101861163B1 (ko) * 2017-04-26 2018-05-25 삼천당제약주식회사 안과용 약학 조성물
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
US20200255496A1 (en) 2017-09-18 2020-08-13 Amgen Inc. Vegfr-fc fusion protein formulations
CN107595765A (zh) 2017-09-22 2018-01-19 沈阳兴齐眼药股份有限公司 一种眼用缓释药物递送系统及其制备方法
WO2019099921A2 (en) 2017-11-17 2019-05-23 Amgen Inc. Vegfr-fc fusion protein formulations
MY202872A (en) 2017-11-20 2024-05-28 Just Evotec Biologics Inc Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
EP3730126B1 (en) 2017-12-22 2025-05-14 Samsung Bioepis Co., Ltd. Liquid composition comprising vegf antagonist
WO2019173767A1 (en) * 2018-03-08 2019-09-12 Coherus Biosciences Inc. Stable aqueous formulations of aflibercept
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
WO2020055123A1 (ko) 2018-09-10 2020-03-19 삼성바이오에피스 주식회사 단백질을 포함하는 액상 조성물
US20210353713A1 (en) 2018-10-26 2021-11-18 Amgen Inc. Formulations comprising a tris buffer and a protein
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
GB201911461D0 (en) 2019-08-09 2019-09-25 Arecor Ltd Novel composition
WO2021050687A1 (en) 2019-09-10 2021-03-18 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept

Similar Documents

Publication Publication Date Title
JP2023055780A5 (cg-RX-API-DMAC7.html)
JP2020138981A5 (cg-RX-API-DMAC7.html)
JP2022166006A5 (cg-RX-API-DMAC7.html)
JP2020183387A5 (cg-RX-API-DMAC7.html)
JP2025163108A5 (cg-RX-API-DMAC7.html)
ES2286119T3 (es) Composicion de recubrimiento para enmascarar el sabor.
JP2021169467A5 (cg-RX-API-DMAC7.html)
ES2240113T3 (es) Cristales de lansoprazol.
JP2021503485A5 (cg-RX-API-DMAC7.html)
JP2025148550A5 (cg-RX-API-DMAC7.html)
CN116712552A (zh) 用于治疗疱疹病毒诱导的病况的方法和组合物
JP2017516847A5 (cg-RX-API-DMAC7.html)
JPS61115023A (ja) イブプロフェンを含有する薬剤学的製剤およびその製造法
US20090220621A1 (en) Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
JP2022174082A5 (cg-RX-API-DMAC7.html)
JP2022512704A5 (cg-RX-API-DMAC7.html)
JP2019534863A5 (cg-RX-API-DMAC7.html)
BR112018001859B1 (pt) Comprimido, e, método para produzir um comprimido
JP2010529999A5 (cg-RX-API-DMAC7.html)
JP2025090691A5 (cg-RX-API-DMAC7.html)
JP2019536761A5 (cg-RX-API-DMAC7.html)
JP2021521171A5 (cg-RX-API-DMAC7.html)
JP2023011601A5 (cg-RX-API-DMAC7.html)
JP2023076632A5 (cg-RX-API-DMAC7.html)
JP2022539077A5 (cg-RX-API-DMAC7.html)